...
tak-img

Takeda Pharmaceutical Co Ltd ADR, Common Stock

TAK

NYQ

$13.1

+$0.09

(0.69%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$41.95B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
22.0508
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.85M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
5.01%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.46
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$12.29 L
$14.73 H
$13.1

About Takeda Pharmaceutical Co Ltd ADR, Common Stock

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameTAKSectorS&P500
1-Week Return-2.38%-2.12%-3%
1-Month Return-1.43%-3.42%-0.73%
3-Month Return-11.49%-11.13%2.87%
6-Month Return3.89%-5.74%7.17%
1-Year Return-4.31%3.97%25.31%
3-Year Return-5.76%1.05%28.38%
5-Year Return-34.76%34.37%81.89%
10-Year Return-37.9%97.88%183.27%

Financials

Mar '20Mar '21Mar '22Mar '23Mar '245YR TREND
Total Revenue3.29T3.20T3.57T4.03T4.26T[{"date":"2020-03-31","value":77.19,"profit":true},{"date":"2021-03-31","value":75,"profit":true},{"date":"2022-03-31","value":83.71,"profit":true},{"date":"2023-03-31","value":94.46,"profit":true},{"date":"2024-03-31","value":100,"profit":true}]
Cost of Revenue1.09T994.31B1.11T1.24T1.43T[{"date":"2020-03-31","value":76.13,"profit":true},{"date":"2021-03-31","value":69.46,"profit":true},{"date":"2022-03-31","value":77.32,"profit":true},{"date":"2023-03-31","value":86.91,"profit":true},{"date":"2024-03-31","value":100,"profit":true}]
Gross Profit2.20T2.20T2.46T2.78T2.83T[{"date":"2020-03-31","value":77.73,"profit":true},{"date":"2021-03-31","value":77.8,"profit":true},{"date":"2022-03-31","value":86.93,"profit":true},{"date":"2023-03-31","value":98.28,"profit":true},{"date":"2024-03-31","value":100,"profit":true}]
Gross Margin66.89%68.91%68.99%69.11%66.43%[{"date":"2020-03-31","value":96.78,"profit":true},{"date":"2021-03-31","value":99.71,"profit":true},{"date":"2022-03-31","value":99.82,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":96.12,"profit":true}]
Operating Expenses2.10T1.69T2.00T2.29T2.62T[{"date":"2020-03-31","value":80.25,"profit":true},{"date":"2021-03-31","value":64.71,"profit":true},{"date":"2022-03-31","value":76.44,"profit":true},{"date":"2023-03-31","value":87.58,"profit":true},{"date":"2024-03-31","value":100,"profit":true}]
Operating Income100.41B509.27B460.84B490.50B214.07B[{"date":"2020-03-31","value":19.72,"profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":90.49,"profit":true},{"date":"2023-03-31","value":96.32,"profit":true},{"date":"2024-03-31","value":42.04,"profit":true}]
Total Non-Operating Income/Expense(307.81B)(286.14B)(301.18B)(222.20B)(301.75B)[{"date":"2020-03-31","value":-30781100000000,"profit":false},{"date":"2021-03-31","value":-28614400000000,"profit":false},{"date":"2022-03-31","value":-30118000000000,"profit":false},{"date":"2023-03-31","value":-22220000000000,"profit":false},{"date":"2024-03-31","value":-30174700000000,"profit":false}]
Pre-Tax Income(60.75B)366.24B302.57B375.09B52.79B[{"date":"2020-03-31","value":-16.2,"profit":false},{"date":"2021-03-31","value":97.64,"profit":true},{"date":"2022-03-31","value":80.67,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":14.07,"profit":true}]
Income Taxes(105.04B)(9.94B)72.41B58.05B(91.41B)[{"date":"2020-03-31","value":-145.08,"profit":false},{"date":"2021-03-31","value":-13.72,"profit":false},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":80.18,"profit":true},{"date":"2024-03-31","value":-126.24,"profit":false}]
Income After Taxes44.29B376.17B230.17B317.04B144.20B[{"date":"2020-03-31","value":11.77,"profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":61.19,"profit":true},{"date":"2023-03-31","value":84.28,"profit":true},{"date":"2024-03-31","value":38.33,"profit":true}]
Income From Continuous Operations44.29B376.17B230.17B317.04B144.20B[{"date":"2020-03-31","value":11.77,"profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":61.19,"profit":true},{"date":"2023-03-31","value":84.28,"profit":true},{"date":"2024-03-31","value":38.33,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Net Income44.24B376.00B230.06B317.02B144.07B[{"date":"2020-03-31","value":11.77,"profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":61.19,"profit":true},{"date":"2023-03-31","value":84.31,"profit":true},{"date":"2024-03-31","value":38.32,"profit":true}]
EPS (Diluted)3.6528.540.670.7618.49[{"date":"2020-03-31","value":12.78,"profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":2.35,"profit":true},{"date":"2023-03-31","value":2.65,"profit":true},{"date":"2024-03-31","value":64.77,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

TAK
Cash Ratio 0.38
Current Ratio 1.28
Quick Ratio 0.77

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

TAK
ROA (LTM) 2.78%
ROE (LTM) 4.15%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

TAK
Debt Ratio Lower is generally better. Negative is bad. 0.53
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.47

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

TAK
Trailing PE 22.20
Forward PE 36.10
P/S (TTM) 0.01
P/B 0.92
Price/FCF 0
EV/R 2.34
EV/Ebitda 9.11
PEG 1.63

FAQs

What is Takeda Pharmaceutical Co Ltd ADR share price today?

Takeda Pharmaceutical Co Ltd ADR (TAK) share price today is $13.1

Can Indians buy Takeda Pharmaceutical Co Ltd ADR shares?

Yes, Indians can buy shares of Takeda Pharmaceutical Co Ltd ADR (TAK) on Vested. To buy Takeda Pharmaceutical Co Ltd ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TAK stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Takeda Pharmaceutical Co Ltd ADR be purchased?

Yes, you can purchase fractional shares of Takeda Pharmaceutical Co Ltd ADR (TAK) via the Vested app. You can start investing in Takeda Pharmaceutical Co Ltd ADR (TAK) with a minimum investment of $1.

How to invest in Takeda Pharmaceutical Co Ltd ADR shares from India?

You can invest in shares of Takeda Pharmaceutical Co Ltd ADR (TAK) via Vested in three simple steps:

  • Click on Sign Up or Invest in TAK stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Takeda Pharmaceutical Co Ltd ADR shares
What is Takeda Pharmaceutical Co Ltd ADR 52-week high and low stock price?

The 52-week high price of Takeda Pharmaceutical Co Ltd ADR (TAK) is $14.73. The 52-week low price of Takeda Pharmaceutical Co Ltd ADR (TAK) is $12.29.

What is Takeda Pharmaceutical Co Ltd ADR price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Takeda Pharmaceutical Co Ltd ADR (TAK) is 22.0508

What is Takeda Pharmaceutical Co Ltd ADR price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Takeda Pharmaceutical Co Ltd ADR (TAK) is 0.92

What is Takeda Pharmaceutical Co Ltd ADR dividend yield?

The dividend yield of Takeda Pharmaceutical Co Ltd ADR (TAK) is 5.01%

What is the Market Cap of Takeda Pharmaceutical Co Ltd ADR?

The market capitalization of Takeda Pharmaceutical Co Ltd ADR (TAK) is $41.95B

What is Takeda Pharmaceutical Co Ltd ADR’s stock symbol?

The stock symbol (or ticker) of Takeda Pharmaceutical Co Ltd ADR is TAK

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top